Technical Analysis for EYPT - EyePoint Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 2.26 -5.83% -0.14
EYPT closed down 5.83 percent on Friday, January 18, 2019, on 82 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Feb 6

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical EYPT trend table...

Date Alert Name Type % Chg
Jan 18 Bearish Engulfing Bearish 0.00%
Jan 18 Stochastic Sell Signal Bearish 0.00%
Jan 18 200 DMA Support Bullish 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Wide Bands Range Expansion -5.83%
Jan 17 Overbought Stochastic Strength -5.83%
Jan 16 Shooting Star Candlestick Bearish -2.59%
Jan 16 Wide Bands Range Expansion -2.59%
Jan 16 Overbought Stochastic Strength -2.59%

Older signals for EYPT ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. In addition, the company has developed DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. Further, it develops YUTIQ shorter-actinguveitis for the treatment of posterior segment uveitis; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Additionally, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It sells its products primarily in the United States and Europe. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, and Enigma Therapeutics Limited. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Is EYPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.94
52 Week Low 0.93
Average Volume 401,531
200-Day Moving Average 2.2398
50-Day Moving Average 2.144
20-Day Moving Average 2.0535
10-Day Moving Average 2.279
Average True Range 0.2084
ADX 16.13
+DI 19.806
-DI 16.5673
Chandelier Exit (Long, 3 ATRs ) 1.8748
Chandelier Exit (Short, 3 ATRs ) 1.8652
Upper Bollinger Band 2.5879
Lower Bollinger Band 1.5191
Percent B (%b) 0.69
BandWidth 52.047723
MACD Line 0.0573
MACD Signal Line 0.0193
MACD Histogram 0.038
Fundamentals Value
Market Cap 88.98 Million
Num Shares 39.4 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -4.35
Price-to-Sales 6.21
Price-to-Book 3.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.62
Resistance 3 (R3) 2.64 2.55 2.56
Resistance 2 (R2) 2.55 2.45 2.54 2.54
Resistance 1 (R1) 2.40 2.40 2.36 2.38 2.52
Pivot Point 2.31 2.31 2.28 2.30 2.31
Support 1 (S1) 2.16 2.21 2.12 2.14 2.00
Support 2 (S2) 2.07 2.16 2.06 1.98
Support 3 (S3) 1.92 2.07 1.96
Support 4 (S4) 1.90